Texas Oncology

Futó vizsgálatok

• Toboroz

  A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

  NCT07768189· 3. fázis· Forrás

• Toboroz

  D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

  NCT06622057· 3. fázis· Forrás

• Toboroz

  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  NCT07185997· 3. fázis· Forrás

• Toboroz

  Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

  NCT06784752· 3. fázis· Forrás

• Toboroz

  Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

  NCT06780670· 2/3. fázis· Forrás

• Toboroz

  A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

  NCT06369285· 2. fázis· Forrás

• Toboroz

  A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  NCT06246916· 3. fázis· Forrás

• Toboroz

  VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

  NCT06264180· 3. fázis· Forrás

• Toboroz

  A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

  NCT06234605· 1. fázis· Forrás

• Fut, nem toboroz

  Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

  NCT05384587· 2. fázis· Forrás

• Toboroz

  Asciminib Roll-over Study

  NCT04877522· 4. fázis· Forrás

• Fut, nem toboroz

  Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

  NCT04919226· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

  NCT04971226· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

  NCT04562389· 3. fázis· Forrás

• Fut, nem toboroz

  Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

  NCT04416984· 1/2. fázis· Forrás

• Toboroz

  Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

  NCT03435796· 2/3. fázis· Forrás

• Toboroz

  A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

  NCT03526835· 1/2. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Gyermekkori daganatok4 toboroz
• Fej-nyaki daganatok2 toboroz
• Melanóma2 toboroz
• Akut limfoid leukémia (ALL)1 toboroz
• Áttétes emlőrák1 toboroz
• Gyomor- és nyelőcsőrák1 toboroz
• Krónikus mieloid leukémia (CML)1 toboroz
• Máj- és epeúti rák1 toboroz
• Mieloproliferatív neopláziák1 toboroz
• Neuroendokrin daganatok1 toboroz
• Prosztatarák1 toboroz
• Tüdőrák1 toboroz
• Vastagbélrák1 toboroz
• Vesedaganat1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Visszavonták

  Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

  NCT05948462· 2. fázis· Forrás

• Lezárult

  Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

  NCT05997056· 2. fázis· Forrás

• Visszavonták

  A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

  NCT05279859· 1/2. fázis· Forrás

• Lezárult

  Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

  NCT04666259· 3. fázis· Forrás

• Lezárult

  Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

  NCT04609566· 2. fázis· Forrás

• Lezárult

  A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

  NCT04620330· 2. fázis· Forrás

• Lezárult

  REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

  NCT04526106· 1/2. fázis· Forrás

• Lezárult

  Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

  NCT03056755· 2. fázis· Forrás

• Lezárult

  Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

  NCT01844505· 3. fázis· Forrás